imidazole has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 2 studies
imidazole: RN given refers to parent cpd
1H-imidazole : An imidazole tautomer which has the migrating hydrogen at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Our previous study reported that nitroxoline, an FDA approved antibiotic, showed potential BRD4 inhibitory activity and antiproliferation activity against leukemia cell lines." | 3.91 | Rational design of 5-((1H-imidazol-1-yl)methyl)quinolin-8-ol derivatives as novel bromodomain-containing protein 4 inhibitors. ( Chen, K; Hu, T; Jiang, H; Jiang, X; Luo, C; Luo, X; Qiao, G; Shen, J; Wang, J; Wang, X; Xing, J; Yang, F; Zhang, R; Zheng, M, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xing, J | 1 |
| Zhang, R | 1 |
| Jiang, X | 1 |
| Hu, T | 1 |
| Wang, X | 1 |
| Qiao, G | 1 |
| Wang, J | 1 |
| Yang, F | 1 |
| Luo, X | 1 |
| Chen, K | 1 |
| Shen, J | 1 |
| Luo, C | 1 |
| Jiang, H | 1 |
| Zheng, M | 1 |
| Jiang, Z | 1 |
| Wang, Y | 1 |
| Sun, L | 1 |
| Yuan, B | 1 |
| Tian, Y | 1 |
| Xiang, L | 1 |
| Li, Y | 2 |
| Li, J | 1 |
| Wu, A | 1 |
2 other studies available for imidazole and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Rational design of 5-((1H-imidazol-1-yl)methyl)quinolin-8-ol derivatives as novel bromodomain-containing protein 4 inhibitors.
Topics: Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Computer-Aided Design; Drug Design; Human | 2019 |
Dual ATP and pH responsive ZIF-90 nanosystem with favorable biocompatibility and facile post-modification improves therapeutic outcomes of triple negative breast cancer in vivo.
Topics: Adenosine Triphosphate; Animals; Antibiotics, Antineoplastic; Biocompatible Materials; Cell Line, Tu | 2019 |